In preclinical models, treatment with a glucose inhibitor can induce Disulfideptosis in cancer cells with high expression of SLC7A11, effectively suppressing tumor growth, and it has no significant toxicity to normal tissues [3]. This evidence concerns the gene SLC7A11 and cancer.